A 4-Week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexibly-dosed, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adult Subjects With Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs SEP 363856 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 30 Nov 2017 Planned End Date changed from 1 Aug 2018 to 31 Aug 2018.
- 30 Nov 2017 Planned primary completion date changed from 1 Aug 2018 to 31 Aug 2018.
- 08 Nov 2016 New trial record